关键词： 5-FU, 5-Flurouracil ABCB, ATP Binding Cassette Subfamily B Member AIF, Apoptosis-inducing factor AKT, Serine/threonine kinase ASGPR, The asialoglycoprotein receptor ASO, Antisense oligonucleotides Anti-cancer drugs BBB, Blood-brain barrier BCRP, Breast cancer-resistant protein Bak, Bcl2-antagonist/killer Bax, Bcl-2-associated X protein apoptotic activator Bcl-2, B-cell lymphoma 2 Bcl-xl, B-cell lymphoma-extra large CAV-1, Caveolin 1 CDK, Cyclin-dependent kinase CI, Combination index CMD, Carboxymethyl dextran CPT, Camptothecin CSCs, Cancer stem cells CT, The computed tomography ChNPs, Chitosan nanoparticles Chemoresistance reversal CisPt, Cisplatin Combination therapy DMSO, Dimethyl sulfoxide DOPE, Dioleoylphosphatidylethanolamine DOTAP, 1,2-Dioleoyl-3-trimethylammonium propane DOX, Doxorubicin DSPE, 1,2-Distearoyl-sn-glycerol-3-phosphoethanolamine DTX, Docetaxel E-CAD, E-cadherin EC50, The half maximal effective concentration EGFR, Epidermal growth factor receptor EPR, The enhanced permeability and retention ERK, Extracellular regulated kinase EZH2, Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit FAK, Focal adhesion kinase FRα, Folate receptor-α GEM, Gemcitabine GSH, Glutathione GalNAc, N-acetylgalactosamine GnRH, Gonadotropin-releasing hormone H1F1, Hypoxia-inducible factor 1 HRAS, GTPase HRas enzyme IC50, The half-maximal inhibitory concentration IL-17B, Interleukin 17B ILK, Integrin-linked kinase Kras, Kirsten rat sarcoma GTPase enzyme LDL, Low-density lipoprotein LHRH, Luteinizing hormone-releasing hormone LHSSG2C, Ditetradecyl 2-(4-(2-(2-(2-(2-(2,6-diaminohexanamido)-3-(1H-imidazole-4-yl) propanamido) ethyl) disulfanyl) ethylamino)-4-oxobutanamido) pentanedioate LRP, Lung resistant protein MAPK, Mitogen-activated protein kinase MDM, Mixed dendrimer micelles MDR, Multidrug-resistant MRI, Magnetic resonance images MSNRs, Mesoporous silica nanorods MTDH, Metadherin MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide MVP, Major vault protein NF-κB, Nuclear factor-kappa light chain enhancer of activated B cells Nanoparticles Notch-1, Notch homolog 1, translocation-associated Nucleic acids OEI, Oligoethylenimine ORF, Open reading frame OxaPt, Oxaliplatin P-gp, P-glycoprotein PAH, Poly (acrylhydrazine) PAMAM, Polyamidoamine PBS, Phosphate Buffered Saline PDMAPMA, Poly (3-dimethylaminopropyl methacrylamide) PDX, Patient-derived xenograft PEG, Polyethylene glycol PEI, Polyethyleneimine PI3-kinase, Phosphatidylinositol 3′-kinase PLA, Polylactic acid PLGA, Poly (lactic-co-glycolic acid) PTEN, Phosphatase and tensin homolog PTK-1, Protein tyrosine kinase 1 PTX, Paclitaxel Polζ, Translesion DNA polymerase Q, Combination efficacy R, Resistance index RES, Reticuloendothelial system REV, Reversionless phenotype RGD, The tripeptide arginine−glycine−aspartic sequence RISC, RNA Induced Silencing Complex Rac1, Ras-related C3 botulinum toxin substrate 1 SIP-1, Stress-induced protein 1 SLN, Solid lipid nanoparticles SR-BI, Scavenger receptor class B type I SSRTs, Somatostatin receptors STAT-3, Signal transducer and activator of transcription 3 TGN, Brain targeting peptide TIMP3, Tissue inhibitor of metalloproteinase 3 TLR4, Toll-like receptor 4 TLS, Translesion synthesis TRAIL, Tumor necrosis factor (TNF)-related apoptosis-inducing ligand USP9X, Ubiquitin specific peptidase 9, X-linked VEGF, Vascular endothelial growth factor ZEB, Zinc finger E-box-binding homeobox 1 transcription factor c-Myc, C-Master regulator of cell cycle entry, proliferative and metabolism miRNA, Micro ribonucleic acid p27Kip1, Cell cycle inhibitor pAKT, Phosphatidylinositol 3-kinase and Protein Kinase pDNA, Plasmid deoxyribonucleic acid shRNA, Short hairpin ribonucleic acid siRNA, Small interfering ribonucleic acid

来  源：   DOI：10.1016/j.ijpx.2022.100126   PDF(Pubmed)

Abstract：
Chemoresistance and hence the consequent treatment failure is considerably challenging in clinical cancer therapeutics. The understanding of the genetic variations in chemoresistance acquisition encouraged the use of gene modulatory approaches to restore anti-cancer drug efficacy. Many smart nanoparticles are designed and optimized to mediate combinational therapy between nucleic acid and anti-cancer drugs. This review aims to define a rational design of such co-loaded nanocarriers with the aim of chemoresistance reversal at various cellular levels to improve the therapeutic outcome of anticancer treatment. Going through the principles of therapeutics loading, physicochemical characteristics tuning, and different nanocarrier modifications, also looking at combination effectiveness on chemosensitivity restoration. Up to now, these emerging nanocarriers are in development status but are expected to introduce outstanding outcomes.
摘要：
化学抗性以及由此产生的治疗失败在临床癌症治疗中是相当具有挑战性的。对化学抗性获得中的遗传变异的理解鼓励了使用基因调节方法来恢复抗癌药物的功效。许多智能纳米粒子被设计和优化以介导核酸和抗癌药物之间的组合治疗。这篇综述旨在定义这种共负载纳米载体的合理设计，目的是在各种细胞水平上逆转化学抗性，以改善抗癌治疗的治疗效果。通过治疗加载的原则，物理化学特性调整，和不同的纳米载体修饰，还研究了联合药物对化学敏感性恢复的有效性。到目前为止,这些新兴的纳米载体处于发展状态，但有望带来出色的成果。
公众号